1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


TABLE 2: 
Total number of patients evaluable at each time and proportion with leukoencephalopathy*
Low RiskStandard/High Risk
LE/Eval (n)T1T2LE/Eval (n)T1T2
Post 1 IV-MTX3/213147/2342
Post 4 IV-MTX12/2011612/21123
Post 7 IV-MTX14/2113918/211413
End of Therapy8/20768/1765
  • Note.—LE indicates leukoencephalopathy; Eval, evaluated; IV-MTX, intravenous methotrexate.
  • * Note that quantitative T1 and T2 measurements were acquired at the end of the imaging studies and often suffered from motion of patients, making them inevaluable.